Albumin-Binding Domains in Therapeutic Protein Engineering: A Structural and Computational Perspective on Rational...

Area of Science:

• Biotechnology
• Protein Engineering
• Pharmacokinetics

Background:

• Therapeutic proteins often have short circulation times, limiting their effectiveness.
• Albumin-binding domains (ABDs) enhance protein half-life by leveraging serum albumin's long lifespan.
• Approved drugs like ozoralizumab validate the ABD approach for extended therapeutic action.

Purpose of the Study:

• To analyze the design principles of albumin-binding domain (ABD)-fusion proteins.
• To provide a framework for rational engineering of long-acting biotherapeutics.
• To integrate structural biology, computational prediction, and experimental validation for ABD-fusion design.

Main Methods:

• Cataloging and comparing various albumin-binding modalities (e.g., bacterial domains, peptides, antibody fragments).
• Analyzing linker architectures and their impact on fusion protein properties.
• Evaluating computational structure prediction tools for ABD-fusion design.
• Establishing guidelines for integrating computational screening with experimental validation.

Main Results:

• Identified key classes of ABDs and compared their characteristics (binding, size, reactivity, cost).
• Demonstrated that flexible glycine-serine linkers, like (GGGGS)3, offer an optimal balance for ABD-fusion proteins.
• Highlighted the profound influence of linker choice on spatial separation, binding affinity, stability, and pharmacokinetics.
• Assessed the utility and limitations of structure prediction tools in ABD-fusion design.

Conclusions:

• ABD-fusion technology offers a robust strategy for developing long-acting protein therapeutics.
• Rational design requires synergistic integration of structural insights, computational predictions, and experimental validation.
• This review provides a comprehensive framework to guide protein engineers and synthetic biologists in developing next-generation biotherapeutics.